The C-terminal domain V of perlecan promotes beta1 integrin-mediated cell adhesion, binds heparin, nidogen and fibulin-2 and can be modified by glycosaminoglycans
about
Perlecan controls neurogenesis in the developing telencephalonForm and function: the laminin family of heterotrimersPerlecan protein core interacts with extracellular matrix protein 1 (ECM1), a glycoprotein involved in bone formation and angiogenesisRibozyme-mediated perlecan knockdown impairs chondrogenic differentiation of C3H10T1/2 fibroblasts.Structural and functional mutations of the perlecan gene cause Schwartz-Jampel syndrome, with myotonic myopathy and chondrodysplasiaDevelopmental and pathogenic mechanisms of basement membrane assemblyPerlecan maintains the integrity of cartilage and some basement membranesChondrogenic activity of the heparan sulfate proteoglycan perlecan maps to the N-terminal domain ICan we produce heparin/heparan sulfate biomimetics using "mother-nature" as the gold standard?Fibroblast growth factor-binding protein is a novel partner for perlecan protein coreThe protein core of the proteoglycan perlecan binds specifically to fibroblast growth factor-7The leucine-rich repeat protein PRELP binds perlecan and collagens and may function as a basement membrane anchorAugmented synthesis and differential localization of heparan sulfate proteoglycans in Duchenne muscular dystrophyWARP is a novel multimeric component of the chondrocyte pericellular matrix that interacts with perlecanDisruption of perlecan binding and matrix assembly by post-translational or genetic disruption of dystroglycan function.A novel interaction between perlecan protein core and progranulin: potential effects on tumor growth.Angiopoietin-3 is tethered on the cell surface via heparan sulfate proteoglycansNot all perlecans are created equal: interactions with fibroblast growth factor (FGF) 2 and FGF receptors.Perlecan-stimulated nodules undergo chondrogenic maturation in response to rhBMP-2 treatment in vitro.Prodomains of transforming growth factor beta (TGFbeta) superfamily members specify different functions: extracellular matrix interactions and growth factor bioavailability.Perlecan and tumor angiogenesis.Perlecan modulates VEGF signaling and is essential for vascularization in endochondral bone formation.Amyloid accomplices and enforcersLinker molecules between laminins and dystroglycan ameliorate laminin-alpha2-deficient muscular dystrophy at all disease stagesA biomechanical role for perlecan in the pericellular matrix of articular cartilageThe role of heparan sulfate and perlecan in bone-regenerative procedures.Endostatin and endorepellin: A common route of action for similar angiostatic cancer avengersPerlecan expression influences the keratin 15-positive cell population fate in the epidermis of aging skinHeparan sulfate proteoglycans: a GAGgle of skeletal-hematopoietic regulators.Synovial perlecan is required for osteophyte formation in knee osteoarthritis.Border patrol: insights into the unique role of perlecan/heparan sulfate proteoglycan 2 at cell and tissue bordersPerlecan immunolocalizes to perichondrial vessels and canals in human fetal cartilaginous primordia in early vascular and matrix remodeling events associated with diarthrodial joint development.Recombinant production of proteoglycans and their bioactive domains.Epidermal transformation leads to increased perlecan synthesis with heparin-binding-growth-factor affinity.Targeting perlecan in human keratinocytes reveals novel roles for perlecan in epidermal formation.Perlecan/Hspg2 deficiency alters the pericellular space of the lacunocanalicular system surrounding osteocytic processes in cortical bone.Gene structure and functional analysis of the mouse nidogen-2 gene: nidogen-2 is not essential for basement membrane formation in mice.Integrin alpha2beta1 is the required receptor for endorepellin angiostatic activity.A novel peptide sequence in perlecan domain IV supports cell adhesion, spreading and FAK activation.Perlecan domain V of Drosophila melanogaster. Sequence, recombinant analysis and tissue expression.
P2860
Q21284139-C4EF6511-C019-4288-B672-8F2F6B25679DQ22254277-ECB24F21-7FD1-4012-AA20-08B4726746ABQ24295251-D4C02975-01BE-4279-87F0-643F1117C158Q24540423-D51FF959-8FD5-4106-B298-270DFBE4664BQ24563749-C748DDC4-07E7-4140-85F7-F0A53011E527Q24608109-546E665E-95D4-430A-8096-474A9657ECD3Q24680954-06D11F2F-86DF-4431-8355-646564810FA3Q24685603-3C341A0A-13FB-4D65-9B71-FCD025B69E96Q27021503-C068146F-405E-44A5-BF8C-07CC07D601EAQ28142123-B58F7277-F39A-4368-9292-A8C4575CCF41Q28145823-8D2B0992-CB7C-4857-A706-8B8EF61A1C55Q28201679-3E9408AE-FF3A-473D-A65F-B6864D4DF4F8Q28215514-0E2977DD-593D-401C-8CF1-275A3621A041Q28512220-1F6C8F92-3A62-42AF-B4D3-8F6168645AF2Q33289428-0337A541-EA3C-4951-9787-41286364CAB3Q33292070-BBC4FD8F-5B68-413C-A479-50655FF46179Q33914700-6BA0576D-64C9-4DE9-A554-01E92D0A8095Q34114308-C79E9E01-4139-4405-B384-AC6119235CFEQ34419440-D939AA8E-A016-42F0-AE98-407F46E86EDAQ34568322-5DB4E766-EAFB-4E8F-9637-EA3737F61758Q35562693-C7B5BF50-5609-4115-8513-E88BD1199682Q35923316-17279FC4-F4A0-4F87-BC48-211A3B45D2D5Q35970547-F4A4DCE4-AE19-438D-9A35-1DCFC60B8E20Q36118063-3390D23D-9398-4442-86CD-62864AC14FCFQ36219477-B616CD75-4DEF-454B-8934-E52DF79C4E91Q36376753-1BECF59A-C40A-4149-9603-18FF64F4F161Q36578668-AA2D1723-50E8-4AA4-BC4B-8ABCB6C6D3DDQ37049108-5D3EAD2B-B713-4F05-91B6-3DFCFC46B4D4Q37117272-94779437-68B2-4737-A212-D87D2F7B470CQ37349431-0743C964-0C95-40D7-9795-EAE0795FADEEQ37610826-75BFE899-A147-4D15-81ED-B8CC4405A1ECQ37643577-4212EBB9-CBFD-4105-88AD-B4D531757AF7Q38082553-094D90F9-C417-44B2-9234-BE51B26AF7B7Q38302299-DA7F0D63-0341-4350-834B-E2376338C412Q38319148-4C2489DD-F644-4E88-BAF3-B71D842FC059Q38552681-104264EA-5CA0-4146-AC99-4F5C5578AAA8Q39681020-27870960-87C1-436B-8D4D-5B50BCB6BD9AQ40048806-A3AE8B8B-D765-429B-AD37-F52EB1F97311Q40053261-AC130190-7B43-410D-8061-9E650EE81614Q40877947-66F5C390-BE52-441D-A909-5DB15380F5CE
P2860
The C-terminal domain V of perlecan promotes beta1 integrin-mediated cell adhesion, binds heparin, nidogen and fibulin-2 and can be modified by glycosaminoglycans
description
1997 nî lūn-bûn
@nan
1997 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
The C-terminal domain V of per ...... modified by glycosaminoglycans
@ast
The C-terminal domain V of per ...... modified by glycosaminoglycans
@en
The C-terminal domain V of per ...... modified by glycosaminoglycans
@nl
type
label
The C-terminal domain V of per ...... modified by glycosaminoglycans
@ast
The C-terminal domain V of per ...... modified by glycosaminoglycans
@en
The C-terminal domain V of per ...... modified by glycosaminoglycans
@nl
prefLabel
The C-terminal domain V of per ...... modified by glycosaminoglycans
@ast
The C-terminal domain V of per ...... modified by glycosaminoglycans
@en
The C-terminal domain V of per ...... modified by glycosaminoglycans
@nl
P2093
P2860
P1433
P1476
The C-terminal domain V of per ...... modified by glycosaminoglycans
@en
P2093
P2860
P356
10.1111/J.1432-1033.1997.T01-1-00039.X
P407
P577
1997-11-15T00:00:00Z